Interferon Alfa News and Research

RSS
Weight-based taribavirin reduces anemia, increases sustained virologic response

Weight-based taribavirin reduces anemia, increases sustained virologic response

Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C

Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C

LabCorp launches IL-28B gene test for HCV infection

LabCorp launches IL-28B gene test for HCV infection

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Depressive symptoms in patients with HCV infection overlooked

Depressive symptoms in patients with HCV infection overlooked

Investment report on Hemispherx BioPharma

Investment report on Hemispherx BioPharma

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Ribavirin Biopartners 200mg film-coated tablets granted EU marketing approval

Ribavirin Biopartners 200mg film-coated tablets granted EU marketing approval

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough receives FDA recommendation approval for PEGINTRON

HCV treatment study reveals low relapse rate of Pegetron

HCV treatment study reveals low relapse rate of Pegetron

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

FDA approves Avastin plus interferon-alfa for people with metastatic renal cell carcinoma

FDA approves Avastin plus interferon-alfa for people with metastatic renal cell carcinoma

Combination biotherapies safe, promising for melanoma patients

Combination biotherapies safe, promising for melanoma patients

FDA approves Torisel (temsirolimus) for advanced kidney cancer

FDA approves Torisel (temsirolimus) for advanced kidney cancer

Cure for hepatitis C

Cure for hepatitis C

Sunitinib shows promise in treating metastatic renal cell cancer

Sunitinib shows promise in treating metastatic renal cell cancer